November 21st, 2014
Two new agents under development may help curb and prevent hyperkalemia, the common and serious side effect of drugs that inhibit the renin-angiotensin-aldosterone system (RAAS), which are the cornerstones of the treatment of chronic kidney disease and heart failure. … Click here to read the full post on Forbes.
November 3rd, 2014
Tariq Ahmad discusses his research group’s study of clinical phenotypes in patients with chronic systolic heart failure.
October 13th, 2014
For two decades, investigators have been studying the association between neighborhood characteristics and cardiovascular disease. A landmark study from 2001 showed that living in a socioeconomically disadvantaged neighborhood was associated with higher incidence of coronary artery disease. Several studies have also shown an association between neighborhood characteristics, most notably the socioeconomic status (SES) and outcomes […]
September 29th, 2014
Clyde Yancy and Mary Norine Walsh offer their perspectives on the much-discussed PARADIGM-HF trial.
September 15th, 2014
Benjamin Scirica discusses his study group’s new analysis of data from the SAVOR-TIMI 53 randomized, placebo-controlled trial of saxagliptin in patients with type 2 diabetes.
September 11th, 2014
Boback Ziaeian discusses his observational study exploring the benefits of guideline-recommended cardiac resynchronization therapy and ICD therapy in heart failure patients, according to race and ethnicity.
September 8th, 2014
This week’s topics include the PARADIGM-HF trial, sham controls in medical-device trials, the efficacy of β blockers in patients with heart failure and atrial fibrillation, and more.
September 5th, 2014
The Editors present a distillation of reader comments on a popular post.
September 1st, 2014
Vinay Prasad explores three reasons why clinicians should have reservations about the findings from PARADIGM-HF.
August 30th, 2014
John J.V. McMurray and Milton Packer, the two lead authors of the PARADIGM-HF trial, discuss the randomized comparison of angiotensin–neprilysin inhibition with the ACE inhibitor enalapril.